Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Gyre Therapeutics (GYRE) over the last 5 years, with Sep 2025 value amounting to $15.3 million.

  • Gyre Therapeutics' Cost of Revenue rose 11.89% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year increase of 1.93%. This contributed to the annual value of $57.5 million for FY2024, which is 5.96% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Cost of Revenue stood at $15.3 million, which was up 0.88% from $15.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Cost of Revenue registered a high of $53.4 million during Q4 2022, and its lowest value of $798,000 during Q1 2022.
  • For the 3-year period, Gyre Therapeutics' Cost of Revenue averaged around $14.5 million, with its median value being $14.4 million (2024).
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 2,077.67% in 2022, then slumped by 69.19% in 2023.
  • Gyre Therapeutics' Cost of Revenue (Quarterly) stood at $2.5 million in 2021, then skyrocketed by 2,077.67% to $53.4 million in 2022, then crashed by 69.19% to $16.5 million in 2023, then rose by 2.38% to $16.9 million in 2024, then grew by 11.89% to $15.3 million in 2025.
  • Its Cost of Revenue was $15.3 million in Q3 2025, compared to $15.2 million in Q2 2025 and $10.8 million in Q1 2025.